

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/820,144
Filing Date April 8, 2004
First Named Inventor Esther H. Chang
Group Art Unit 1632
Examiner Name

Sheet 1 of 2 Attorney Docket Number 2444-116

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
SL	AA	5,693,509		Cotten et al.	Dec. 12, 1997
I	AB	5,962,311		Wickham et al.	Oct. 5, 1999
I	AC	5,994,109		Woo et al.	Nov. 30, 1999
SL	AD	6,410,010		Zhang et al.	Jun 25, 2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
SL	AE	WO	94/24299		Boehringer Ingelheim Int'l GmbH	Oct. 27, 1994	
I	AF	WO	97/38723		Immusol Inc.	Oct. 23, 1997	
SL	AG	WO	98/40508		Barbara Sosnowski et al.	Sep. 17, 1998	

Examiner
Signature


SL Chen

Date
Considered

4-25-2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	2444-116

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
gm	AH	CARDUCCI et al., <i>Renal, Bladder and Prostate Cancers: Gene Therapy; Diagnosis and Treatment of Genitourinary Malignancies</i> , 1996, Kluwer Academic Publishers, Boston.	
	AI	COOPER, <i>Oncogenes</i> , by Jones and Bartlett Publishers; ISBN 0-86720-136-3, 1990	
	AJ	DEONARAIN, "Ligand-targeted receptor-mediated vectors for gene delivery," <i>Expert Opinion on Therapeutics Patents</i> , GB, Ashley Publications, 8(1):53-69, January 1998.	
	AK	DOUGLAS et al., "Targeted adenoviral vectors for cancer gene therapy (Review)," <i>International Journal of Oncology</i> , 11:341-348, 1997	
	AL	ECK et al., <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , McGraw-Hill, New York, pp. 77-101, 1996	
	AM	FEIGELSON et al., "Genetic Susceptibility to Cancer from xogenous and Endogenous Exposures," <i>Journal of Cellular Biochemistry</i> , 255:15-22 (1996)	
	AN	GURA, T., <i>Science</i> , 278:1041-1042, 1997	
	AO	HULME, <i>Receptor-Ligand Interactions-A Practical Approach</i> , Oxford University Press, Walton Street, Oxford OX2 6DP, ISBN 0-19-963090-9	
	AP	MICHAEL et al., "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway," <i>Gene Therapy</i> 1:223-232, 1994.	
	AQ	MILLER et al., "Targeted vectors for gene therapy," <i>FASEB Journal, U.S. Fed. of American Society for Experimental Biology</i> , 9(2): 190-1999, February 1, 1995.	
	AR	Report and Recommendations of the Panel to Assess the NIH Investment Research on Gene Therapy, 12/7/95	
	AS	STAVRIDIS et al., "Construction of Transferrin-Coated Liposomes for In Vivo Transport of Exogenous DNA to Bone Marrow Erythroblasts in Rabbits," given as a communication at the NATO Advanced Studies Institute Conf., Cape Sounioin Beach, Greece, June 20-July 1, 1983.	
	AT	STRYER, <i>Biochemistry</i> , 1995, pp. 7, 8, 33-40, 938-939	
	AU	VERMA et al., <i>Nature</i> , 389:239-242, 1997	
	AV	WAGNER et al., "Transferrin - polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:3410-3414, May 1990.	
gm	AW	XU, "Transferrin-Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation In Vitro," <i>Human Gene Therapy</i> , 8:467-475, March 1, 1997.	

Examiner Signature		Date Considered	4-25-07
--------------------	--	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

U.S. PATENT DOCUMENTS

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
				Confirmation No.	6653
Sheet	2	of	4	Attorney Docket Number	2444-116

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
	AE	PCT	WO 94/24299		Boehringer Ingelheim Int'l GmbH	Oct. 27, 1994	
	AF	PCT	WO 97/38723		Immusol Inc.	Oct. 23, 1997	
	AG	PCT	WO 98/40508		Barbara Sosnowski et al.	Sep. 17, 1998	
Examiner Signature					Date Considered	4-25-07	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
				Confirmation No.	6653
Sheet	3	of	4	Attorney Docket Number	2444-116

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-isside number(s), publisher, city and/or country where published	T ²
	AH	CARDUCCI et al., Rental, Bladder and prostate cancers: gene therapy, Diagnosis and Treatment of Genitourinary Malignancies, 1996, Kluwer Academic Publishers. Boston.	
	AI	COOPER, Oncogenes, 1990 by Jones and Bartlett Publishers; ISBN 0-86720-136-3	
	AJ	DEONARAIN, "Ligand-targeted receptor-mediated vectors for gene delivery," Expert Opinion on Therapeutics Patents, GB, Ashley Publications, 8(1):53-69, January 1998.	
	AK	DOUGLAS et al., "Targeted adenoviral vectors for cancer gene therapy (Review)," <i>International Journal of Oncology</i> , 1997, pp. 341-348, vol. 11.	
	AL	ECK et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 1996, pp. 77-101	
	AM	FEIGELSON et al., Genetic Susceptibility to Cancer from exogenous and Endogenous Exposures; <i>Journal of Cellular Biochemistry</i> , 1996, pp. 15-22, vol. 255	
	AN	GURA, T., "Systems for Identifying New Drugs Are Often Faulty," <i>Science</i> , November 7, 1997, pp. 1041-1042, vol. 278.	
	AO	HULME; Receptor-Ligand Interactions-A practical Approach; Oxford University Press, Walton Street, Oxford OX2 6DP, ISBN 0-19-963090-9.	
	AP	MICHAEL et al., "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway," <i>Gene Therapy</i> 1:223-232, 1994.	
	AQ	MILLER et al., "Targeted vectors for gene therapy," <i>FASEB Journal</i> , U.S. Fed. of American Society for Experimental Biology, 9(2): 190-1999, February 1, 1995.	
	AR	Report and Recommendations of the Panel to Assess the NIH Investment Research on Gene Therapy. 12/7/1995.	
	AS	STAVRIDIS et al., "Construction of Transferrin-Coated Liposomes for In Vivo Transport of Exogenous DNA to Bone Marrow Erythroblasts in Rabbits," given as a communication at the NATO Advanced Studies Institute Conf., Cape Souniion Beach, Greece, June 20-July 1, 1983.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/820,144
				Filing Date	April 8, 2004
				First Named Inventor	Esther H. Chang
				Group Art Unit	1632
				Examiner Name	
				Confirmation No.	6653
Sheet	4	of	4	Attorney Docket Number	2444-116

	AT	STRYER, "Reversible Interactions of Biomolecules are Mediated by Three Kinds of Noncovalent Bonds," <i>Biochemistry</i> , 1995, pp. 7, 8, 33-40, 938-939. W.H. Freeman and Company, New York.	
	AU	VERMA et al., "Gene therapy--promises, problems and prospects," <i>Nature</i> , September 18, 1997, pp. 239-242, vol. 389.	
	AV	WAGNER et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:3410/3414, May 1990.	
	AW	XU, "Transferrin-Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation <i>In Vitro</i> ," <i>Human Gene Therapy</i> , 8:467-475, March 1, 1997.	
Examiner Signature			Date Considered 4-25-07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered: Include copy of this form with next communication to applicant.
¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.